ClinicalTrials.gg
CompletedNCT03956953Updated Jun 18, 2020

Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese Subjects

A Phase 1 interventional study of BMS-986165 and Placebo in Autoimmune Diseases, sponsored by Bristol-Myers Squibb. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-18.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2019, 7 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies in Autoimmune Diseases with a site in China — 72 open to participants now, 78 under way, 7 of them phase 3. Autoimmune Diseases · China.

Enrollment
18th of 113
135 · median 30
Started
2019
with 1 other
Phase 1
57 of 125
40 open now
Registered
19th of 125
by date

Among the 125 studies in Autoimmune Diseases with a site in China, this one is the 18th largest by enrollment of the 113 interventional ones that give a count, is one of 2 that started in 2019, is one of 57 in phase 1, and was the 19th registered.

Autoimmune Diseases

803 studies on the registry are indexed under Autoimmune Diseases; 272 are open to participants now.

Browse Autoimmune Diseases studies →

Open to participants now

72 of the 125 studies in Autoimmune Diseases with a site in China are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies in Autoimmune Diseases with a site in China, or all of them as a file.
02

Study summary

Main objective of this study is to assess BMS-986165 plasma PK following single and multiple oral doses of BMS-986165 in healthy Chinese subjects.

03

Conditions studied

  • Autoimmune Diseases

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed .
  • Healthy participants, as determined by physical examination, ECGs, and clinical laboratory and procedure determinations.
  • (BMI) of 18 to 24 kg/m2, inclusive, and total body weight >= 50 kg.

Exclusion criteria

Exclusion Criteria:

  • History of allergy to drug class or related compounds.
  • History or evidence of active infection within 7 days of study day 1.
  • Drug or alcohol abuse within 6 months of study treatment administration.

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    Group 1: BMS-986165 Dose 1

    Participants will receive Dose 1 on Day 1, and from Day 5 - 19.

    Drug: BMS-986165

  • Experimental
    Group 2: BMS-986165 Dose 2

    Participants will receive Dose 2 on Day 1, and from Day 5 - 19.

    Drug: BMS-986165

  • Placebo comparator
    Group 1: Placebo Dose 1

    Participants will receive placebo matching Dose 1 on Day 1, and from Day 5 - 19.

    Other: Placebo

  • Placebo comparator
    Group 2: Placebo Dose 2

    Participants will receive placebo matching Dose 2 on Day 1, and from Day 5 - 19.

    Other: Placebo

Interventions

  • Dose 1 or Dose 2 on Day 1, and from Days 5-19'

  • OtherPlacebo

    Placebo matching Dose 1 or Dose 2 on Day 1, and from Days 5-19

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of BMS-986165

    Time frame: Days 1 to 4, Day 5, and Day 19

  2. Time to Maximum Observed Plasma Concentration (Tmax) of BMS-986165

    Time frame: Days 1 to 4, Day 5, and Day 19

  3. Area Under The Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) of BMS-986165

    Time frame: Days 1 to 4, Day 5, and Day 19

  4. Area Under The Plasma Concentration-Time Curve From Time Zero Extrapolated To Infinite Time (AUC(INF)) of BMS-986165

    Time frame: Day 1 to Day 4

  5. Apparent Plasma Elimination Half-Life (T-HALF) of BMS-986165

    Time frame: Days 1 to 4, Day 5, and Day 19

  6. Apparent Oral Total Body Clearance (CLT/F) of BMS-986165

    Time frame: Days 1 to 4, Day 5, and Day 19

  7. Metabolic Ratio for AUC(INF) of Metabolite (BMT-153261 and BMT-158170) Over Parent (BMS-986165) - MR(AUC[INF])

    Time frame: Day 1 to Day 4

  8. Metabolic Ratio for Cmax of Metabolite (BMT-153261 and BMT-158170) Over Parent (BMS-986165) - MR(Cmax)

    Time frame: Days 1 to 4, Day 5, and Day 19

  9. Apparent Volume of Distribution (Vz/F) of BMS-986165

    Time frame: Days 1 to 4, Day 5, and Day 19

  10. Time to Maximum Observed Plasma Concentration (Tmax) of BMS-986165

    Time frame: Day 5 to Day 19

  11. Area Under the Plasma Concentration-Time Curve in a Dosing Interval (AUC(TAU)) of BMS-986165

    Time frame: Day 5 and Day 19

  12. Effective Elimination Half-Life (T-HALFeff) of BMS-986165

    Time frame: Days 1 to 4, Day 5, and Day 19

  13. Trough Observed Plasma Concentration (Ctrough) of BMS-986165

    Time frame: Day 2 to 20

  14. Average Plasma Concentration at Steady State (Css-avg) of BMS-986165

    Time frame: Days 1 to 4, Day 5, and Day 19

  15. Accumulation Index (AI) of BMS-986165

    Time frame: Days 1 to 4, Day 5, and Day 19

  16. Metabolic Ratio for AUC(TAU) of Metabolite (BMT-153261 and BMT-158170) Over Parent (BMS-986165) - MR(AUC[TAU])

    Time frame: Day 5 to Day 19

  17. Degree of Fluctuation (DF) of BMS-986165

    Time frame: Days 1 to 4, Day 5, and Day 19

Secondary outcomes

  1. Number of participants with Adverse Events (AEs)

    Time frame: Up to Day 31

  2. Number of Participants With Clinically Significant Change in Clinical Laboratory Values

    Time frame: Up to Day 24

  3. Number of Participants With Clinically Significant Change in Vital Signs

    Time frame: Up to Day 24

  4. Number of Participants With Clinically Significant Change in Electrocardiogram (ECG)

    Time frame: Up to Day 24

  5. Number of Participants With Clinically Significant Change in Physical Examination

    Time frame: Up to Day 24

  6. Maximum Observed Plasma Concentration (Cmax) of Metabolites BMT-153261 and BMT-158170

    Time frame: Days 1 to 4, Day 5, and Day 19

  7. Time to Maximum Observed Plasma Concentration (Tmax) of B Metabolites BMT-153261 and BMT-158170

    Time frame: Days 1 to 4, Day 5, and Day 19

  8. Area Under The Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) of Metabolites BMT-153261 and BMT-158170

    Time frame: Days 1 to 4, Day 5, and Day 19

  9. Area Under The Plasma Concentration-Time Curve From Time Zero Extrapolated To Infinite Time (AUC(INF)) of Metabolites BMT-153261 and BMT-158170

    Time frame: Days 1 to 4, Day 5, and Day 19

  10. Apparent Plasma Elimination Half-Life (T-HALF) of Metabolites BMT-153261 and BMT-158170

    Time frame: Days 1 to 4, Day 5, and Day 19

  11. Area Under the Plasma Concentration-Time Curve in a Dosing Interval (AUC(TAU)) of Metabolites BMT-153261 and BMT-158170

    Time frame: Days 1 to 4, Day 5, and Day 19

  12. Effective Elimination Half-Life (T-HALFeff) of Metabolites BMT-153261 and BMT-158170

    Time frame: Days 1 to 4, Day 5, and Day 19

  13. Trough Observed Plasma Concentration (Ctrough) of Metabolites BMT-153261 and BMT-158170

    Time frame: Days 1 to 4, Day 5, and Day 19

  14. Average Plasma Concentration at Steady State (Css-avg) of Metabolites BMT-153261 and BMT-158170

    Time frame: Days 1 to 4, Day 5, and Day 19

  15. Accumulation Index (AI) of Metabolites BMT-153261 and BMT-158170

    Time frame: Days 1 to 4, Day 5, and Day 19

  16. Degree of Fluctuation (DF) of Metabolites BMT-153261 and BMT-158170

    Time frame: Days 1 to 4, Day 5, and Day 19

  17. Total Amount of Drug Recovered in Urine (URt) Following Single Oral Doses of BMS-986165

    Time frame: Day 1 to Day 5

  18. Total Percent of Administered Dose Recovered Unchanged in Urine (%URt) Following Single Oral Doses of BMS-986165

    Time frame: Day 1 to Day 5

  19. Renal Clearance (CLR) Following Single Oral Doses of BMS-986165

    Time frame: Day 1 to Day 5

07

Study locations

1 site
  • Local Institution
    Beijing, Beijing 100029, China
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Sep 2019, 5 months.

Of 69 industry-sponsored phase 1 interventional studies under Autoimmune Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 5 months is below that.

Counting every sponsor, half of 95 studies reached it within 23 months; a quarter within 9 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2019
First posted
May 21, 2019
StartActual
Apr 4, 2019
Primary completionActual
Sep 25, 2019
CompletionActual
Sep 25, 2019
Last update
Jun 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03956953
Responsible party
Sponsor
First posted
May 21, 2019
Start date
Apr 4, 2019
Primary completion
Sep 25, 2019
Completion
Sep 25, 2019
Last update
Jun 18, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion